We just passed a milestone in Group Health history. Last Saturday, our member-elected governing board announced the results of a special vote on Group Health acquisition by Kaiser Permanente. Of eligible member votes received, 85% were in favor of acquisition. So what’s next?
First, thank you to everyone who participated in the vote and everyone at Group Health and Kaiser who worked on negotiations and communications leading to this historic event. The next step is state insurance commission and Federal Trade Commission review. This work may take some time. Meanwhile, Group Health and Group Health Research Institute (GHRI) are looking forward to collaborating with Kaiser on a transition plan. I will be meeting soon with Dawn Loeliger, Group Health executive vice president for strategic planning & development, and others on future planning.
For now, daily operations won’t change much. At GHRI, we’ll continue to excel as a public-interest, mission-driven research institute, diligently pursuing our scientific agenda. In fact, I’m proud that the consistent success of GHRI in practical research that helps people and their families stay healthy is a proven asset we bring to the Kaiser acquisition.
For several reasons, I’ve been reflecting about what makes us a high-performing research institute. Mainly, I want GHRI to continue to be a leading, innovative research enterprise as we join the prestigious, national network of Kaiser research institutes. I’m also reviewing GHRI’s strengths in preparation for our annual Research Advisory Board (RAB) meeting on March 25. I’ll join other Group Health and GHRI leaders in presenting the state of our enterprise to our board of health system experts. This year, our RAB includes Karen Emmons, PhD, vice president for research and director of the Kaiser Foundation Research Institute. My colleague and friend John Steiner, MD, MPH, senior director, Institute for Health Research, Kaiser Permanente Colorado, will be completing his term on our RAB.
I’ll be telling the RAB what GHRI brings to the Kaiser acquisition, for example:
GHRI is well-positioned to be successful as we join our Kaiser colleagues while retaining our core strengths as researchers.
After our presentation to the RAB, I’m looking forward to the informal discussions. We’ll learn more about potential new opportunities such as closer partnership with the Kaiser Permanente Center for Effectiveness and Safety Research (CESR). The CESR multimillion-dollar data infrastructure collects health data with tremendous research potential. We and other CESR users will be using the data to measure the true vital signs of health care performance with a goal of broadly improving care.
I want to emphasize that the overall mission and high performance of GHRI won’t change with the acquisition. We’ll just add our strengths to Kaiser’s larger integrated care, coverage, and research system, which is like Group Health but with a greater national reach. Next month in my newsletter, I’ll report on how our RAB, including our guests from Kaiser, respond to the points I’ve outlined here. I look forward to their input and will tell you what I learned from them.
Eric B. Larson, MD, MPH
Executive Director, Group Health Research Institute
Vice President for Research, Group Health